Exxon Mobil Corp
Change company Symbol lookup
Select an option...
XOM Exxon Mobil Corp
EPD Enterprise Products Partners LP
STLB Sterling Business Solutions Inc
CITY Avalon Correctional Services Inc
TEVJF Teva Pharmaceutical Industries Ltd
UMBF UMB Financial Corp
OXM Oxford Industries Inc
ICON Iconix Brand Group Inc
BAC Bank of America Corp
ON ON Semiconductor Corp
Go

Energy : Oil, Gas & Consumable Fuels | Large Cap Value
Company profile

Exxon Mobil Corporation is engaged in energy business. The Company is engaged in the exploration, production, transportation and sale of crude oil and natural gas, and the manufacture, transportation and sale of petroleum products. The Company also manufactures and markets commodity petrochemicals, including olefins, aromatics, polyethylene and polypropylene plastics, and a range of specialty products. The Company's segments include Upstream, Downstream, Chemical, and Corporate and Financing. The Upstream segment operates to explore for and produce crude oil and natural gas. The Downstream operates to manufacture and sell petroleum products. The Chemical segment operates to manufacture and sell petrochemicals. The Company has exploration and development activities in projects located in the United States, Canada/South America, Europe, Africa, Asia and Australia/Oceania.

Price
Delayed
$44.60
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)

Today's volume of 181,407 shares is on pace to be much lighter than XOM's 10-day average volume of 23,353,446 shares.

181,407

UPDATE: Aurora Cannabis makes its long-awaited push into the U.S. with Reliva CBD acquisition

6:30 am ET May 21, 2020 (MarketWatch)
Print

By Max A. Cherney

Aurora shares surge nearly 30% in the extended session

Over a year after Aurora Cannabis Inc. executives started publicly talking about making a push into the U.S. market, the company has made its move: the $40 million all-stock purchase of a cannabidiol maker called Reliva.

Though Aurora (ACB.T) (ACB.T) will issue roughly 2 million shares to make the purchase, shares rose nearly 30% in the extended session Wednesday.

The closely held Reliva LLC makes products that include cannabidiol, or CBD, which is a non-intoxicating element of the marijuana plant. In the announcement, Aurora said Reliva sells products in 20,000 retail locations in the U.S. and has achieved a non-standard measure of profitability. Set to close in June, Aurora could pay up to $45 million in additional stock beyond the $40 million initial payment.

Don't miss:'CBD has the potential to harm you,' FDA warns consumers (http://www.marketwatch.com/story/cbd-has-the-potential-to-harm-you-fda-warns-consumers-2019-11-25)

In the announcement, Aurora said that Reliva's management team will continue to operate the U.S. business, with its chief executive taking the title of president, U.S.

Reliva's website sells a range of CBD products including drink mix, gummies, lip balm, pet inctures and skin cream.

See also:Cronos paid $300 million for a small CBD company, and CEO's private-equity firm stands to collect $120 million of it (http://www.marketwatch.com/story/cronos-paid-300-million-for-a-small-cbd-company-and-ceos-private-equity-firm-stands-to-collect-120-million-of-it-2019-11-04)

The U.S. recently legalized hemp, but left regulating CBD to the Food and Drug Administration, which has taken a decidedly cautious approach (http://www.marketwatch.com/story/cbd-has-the-potential-to-harm-you-fda-warns-consumers-2019-11-25). At the moment, companies are not allowed to add CBD to food, drinks or cosmetic products, and the FDA has been cracking down on companies that do so (http://www.marketwatch.com/story/curaleaf-shares-tumble-8-after-fda-warning-letter-over-cbd-health-claims-2019-07-23).

The FDA's stance has proven difficult for some of Aurora's competitors. Cronos Group Inc. (CRON.T) said in a recent conference call that it had yanked plans to launch a CBD brand in the U.S (http://www.marketwatch.com/story/cronos-paid-300-million-for-a-small-cbd-company-and-ceos-private-equity-firm-stands-to-collect-120-million-of-it-2019-11-04)., and cited regulatory uncertainty, among other things.

Aurora's stock has been on a roller-coaster ride in the past year, falling to the point of being threatened with delisting before executing a reverse stock split (http://www.marketwatch.com/story/aurora-cannabis-will-roll-up-its-shares-in-a-reverse-stock-split-what-you-need-to-know-2020-04-13) and seeing the newly bundled shares spike (http://www.marketwatch.com/story/aurora-cannabis-shares-skyrocket-on-hopes-worst-is-behind-canadian-weed-company-2020-05-18) -- to twice the market value of rival OrganiGram Holdings Inc.'s (OGI.T) -- after an earnings report that showed better pot sales than expected.

Cannabis Watch: See all of MarketWatch's cannabis coverage here (http://www.marketwatch.com/storyno-meta-for-guid)

-Max A. Cherney; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

May 21, 2020 06:30 ET (10:30 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.